Healthcare News by GLG Council Members

Will Bundles of Healthcare Payments Bring Joy to Anybody?

November 13, 2009

Analysis by: GLG Expert Contributor

Analysis of:RAND: Bundled Payments the Best Way to Contain Healthcare Costs | www.fiercehealthcare.com

Analysts at RAND Corp. have thrown their weight behind the use of bundled fees to pay physicians and hospitals. They have concluded that although difficult to implement, doing so is probably the most effective way to contain health care costs which could spin even more out of control under the current health care reform proposals and ultimately bankrupt the federal government without dramatic changes to the current fee for service system.

Ken PowellPresidentGenesis Business Development, LLC

Epigenomics Reports Excellent 3Q Returns

November 12, 2009

Analysis of:Epigenomics Nearly Quadruples Sales in Q3 | www.genomeweb.com

Germany based Epigenomics posted stellar Q3 financial results and reduced net loss by 8%.  According to the company, the increase comes from existing collaborations, new partnerships, and license agreements

Ken PowellPresidentGenesis Business Development, LLC

New Sample Prep Company

November 12, 2009

Analysis of:Life Technologies to Buy Biotrove, Which Will Form Mass Spec Sample Prep Company | www.biotrove.com

Following on Life Technologies' (NASDAQ: LIFE) acquisition of Biotrove, Biotrove announced in a separate release that it will form a subsidiary for a sample handing company for mass spectroscopy systems.  This could be the real opportunity for future growth.

What are these “Further Adjustments?”

November 11, 2009

Analysis by: GLG Expert Contributor

Analysis of:AHA applauds reform bill, urges further adjustments | www.modernhealthcare.com

Healthcare Reform has passed the House, with some changes from the two versions in the Senate. What are the items that will affect hospitals and what can hospitals expect for margins in the future.

Ken PowellPresidentGenesis Business Development, LLC

Consolidation Continues in Life Sciences

November 11, 2009

Analysis of:Qiagen Acquires SABiosciences for $90M | www.genomeweb.com

Qiagen (NASDAQ: GQEN) has entered into a definitive agreement to acquire privately held SABiosciences for $90 million dollars.  Meanwhile, Life Technologies has entered into a definitive agreement to acquire, the manufacturer of the OpenArray high-throughput gene expression and genotyping system.  Yesterday's announcements are more examples of the high level of consolidation activity occurring in the wide open life sciences space.

Succesful new treatment for Lupus

November 10, 2009

Analysis by: GLG Expert Contributor

Analysis of:GSK & HSG say belimumab met primary endpoints in BLISS-76 phase-3 trials | www.pharmabiz.com

Human Genome Sciences has a potential new and successful therapy for Lupus.

Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance

November 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:Dexamethasone implant a first for macular edema after retinal vein occlusion | ophthalmologytimes.modernmedicine.com

Ozurdex (Allergan) is now on the market and available for ophthalmologists to treat patients with retinal vascular occlusions (RVO).While the technology and treatment may be sound, there may be significant hurdles to overcome from a billing standpoint.Ozurdex may follow the same fate as Lucentis (Genetech).  It must compete with a much cheaper drug which has comparable efficacy.

Solar-Powered Portable Medical Imaging Devices Are Coming Soon

November 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:GE Global Research bags US$ 1.2 mn NIH project for developing technology in prenatal care | www.pharmabiz.com

GE Healthcare appears to be serious in exploring the potential to create portable solar-powered medical imaging devices.  The value of this type of technology in helping to save lives and detect early potential life-threatening medical and surgical conditions affecting people who live in the rural and most remote areas and who are unable to readily obtain access to healthcare services is discussed. 

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC)

What is potential future for Sequenom in prenatal testing.

November 9, 2009

Analysis of:So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com

The historic but minimally supported enthusiasm for the Sequenom prenatal test has previously been reported in this space previously. Even in the absence of data retractions, leading to termination of much of senior management, problems in the rollout of the product should have been anticipated.Remarkably, this article asserts that industry insiders remain optimistic about the development of a successful diagnostic product.

Ken PowellPresidentGenesis Business Development, LLC

Quest Diagnostics to Offer New Colorectal Cancer Test

November 9, 2009

Analysis of:Quest to Offer Septin9 Colorectal Cancer LTD 'Later This Year' | www.genomeweb.com

Quest Diagnostics senior spokesperson Jay Wohlgemuth said that Quest plans to launch a new Laboratory Developed Test (LDT) for colorectal cancer based on Epigenomics’ mSEPT9 DNA-methylation biomarker.  Many companies have searched for a blood-based marker as an effective diagnostic alternative to colonoscopy, which would encourage the 90 million adults over 50 to be screened for colorectal cancer.

Previous Page : 12345678910Next11 to 20 of 7849